BIOCYTOGEN
3.1.2023 15:24:36 CET | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SEHK : 02315) a clinical-stage biotechnology company with a focus on the antibody discovery and development based on its proprietary RenMiceTM Platforms, and Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”, SEHK: 3692), a leading innovation-driven pharmaceutical company with a focus on the treatment of major diseases including oncology, infectious diseases, CNS disorders, metabolic diseases and autoimmune diseases, today announced an antibody collaboration, assignment and exclusive license agreement. Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules against the designated target for the development, manufacturing and commercialization globally. Under the agreement, Biocytogen will receive an upfront payment and will be eligible to receive development and commercial milestones of up to tens of millions of Chinese yuan, as well as single-digit tiered royalties on net sales.
“We are very excited to partner with Hansoh Pharma, one of the largest pharmaceutical companies in China. The licensed antibodies were selected from Biocytogen’s Project Integrum programs and generated from our proprietary fully human antibody RenMiceTM target-knockout mice. The antibodies possess highest possible diversity to improve the success rate of antibody discovery,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Thanks to Hansoh Pharma’s recognition of our RenMiceTM platforms and Project Integrum. We believe Hansoh Pharma’s strong R&D, manufacturing and commercialization capabilities will accelerate the development of RenMiceTM-derived antibody molecules and bring the benefits to patients worldwide.”
About Project Integrum
Project Integrum is a large-scale antibody drug development project for 1000+ potential drug targets using RenMiceTM (RenMabTM, RenLite® and RenNano®) target knockout mice. Different from the traditional mechanism of action (MOA)-based drug development strategy, Project Integrum uses large-scale in vivo drug efficacy screening methods to discover innovative drugs with excellent safety and efficacy. So far, we have completed making RenMiceTM KO for 1000+ targets. In addition, we have developed a large variety of preclinical antibody assets including 10 fully human bispecific antibodies, 20+ bispecific ADCs, 10+ TCR-mimic antibodies, 30+ monoclonal antibodies against novel targets, and 600+ antibody hits. Antibody molecules generated by Project Integrum have high specificity, high affinity and good druggability, which have attracted many top biopharmaceutical companies to obtain a license or reach a drug co-development agreement with us, including Merck KGaA, ADC Therapeutics, Remgen, NJCTTQ, etc.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. This project has resulted in 28 drug co-development agreements and 16 RenMiceTM licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230103005498/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Svante’s Solid Sorbent Filter Technology Named to Fast Company’s 2026 World Changing IdeasAwards List16.6.2026 16:00:00 CEST | Press release
The recognition highlights Svante’s nanoengineered filters for CO₂ capture and removal This year’s awards, featured on fastcompany.com, highlight 191 outstanding projects across 14 categories. Svante Technologies Inc. (Svante), a purpose-driven integrated carbon management company, today announced that its nanoengineered solid sorbent filter technology has been named to Fast Company’s 2026 World Changing Ideas list, one of the world’s most selective recognitions for innovations tackling climate and sustainability challenges. The honour recognizes Svante’s proprietary filter platform, which enables high-performance capture and removal of CO₂ from industrial emissions and the air, as well as other critical gas separation applications, particularly where chemical processes do not perform well. This year’s awards, featured on fastcompany.com, highlight 191 outstanding projects across 14 categories. A panel of Fast Company editors and reporters evaluated more than 1,500 entries based on the
AIRS Medical Welcomes Strategic Growth Investment from TA Associates to Accelerate Global Growth in AI-Powered MRI Solutions16.6.2026 16:00:00 CEST | Press release
Investment supports global expansion and continued innovation in AI-powered MRI technologies that help healthcare providers improve imaging efficiency, increase capacity and expand patient access AIRS Medical (“the Company”), a global leader in AI solutions for medical imaging, today announced a strategic growth investment from TA Associates (“TA”), a leading global private equity firm. The investment will help fuel AIRS Medical’s next phase of global expansion, advancement of its AI-powered radiology technology solutions and ongoing product innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616325248/en/ Founded in 2018, AIRS Medical develops AI-native magnetic resonance imaging (“MRI”) acceleration and reconstruction software designed to support MRI speed, image quality and workflow performance. Healthcare organizations and leading academic institutions are adopting AIRS Medical's technologies to expand imaging
Clearlake Capital Closes on $14.8 Billion to Capitalize on AI-Driven Transformation and Continue Sector-Focused Investment Strategy16.6.2026 15:00:00 CEST | Press release
Fund VIII Reflects Strong Global Investor Support for Clearlake’s Integrated Platform, Operational Value-Creation Model, and AI-Enabled Investment Approach Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced the successful close of its eighth flagship fund, Clearlake Capital Partners VIII (“Fund VIII”), alongside related co-investment vehicles and separately managed accounts. Together, these vehicles represent $14.8 billion of capital commitments and position Clearlake to continue investing behind the secular trends reshaping industries, including artificial intelligence, software modernization, digital transformation, and operational efficiency. The successful fundraise comes amid a highly competitive and selective fundraising environment for private markets and underscores continued investor confidence in Clearlake's different
Gurobi's Research Leadership Recognized Across Leading Scientific Organizations16.6.2026 15:00:00 CEST | Press release
Awards recognize foundational research that helped shape the fields of mixed-integer and nonlinear optimization—and reflect the company’s deep scientific roots. Gurobi Optimization, LLC, the leader in decision intelligence technology, today announced recognitions received by Dr. Edward Rothberg and Dr. Andreas Wächter from leading academic and industry organizations for research that has had lasting impact on the field of optimization. “Gurobi was founded on a commitment to rigorous, applied optimization research,” said Dr. Oliver Bastert, CTO, Gurobi. “And these recognitions are a reflection of that legacy. The foundational work that Ed and Andreas produced continues to shape the field, and that same spirit of scientific innovation drives everything we do today.” Dr. Edward Rothberg, co-founder and Chairman of the Board at Gurobi, was recently honored with the INFORMS Test of Time Paper Award for his paper, “An Evolutionary Algorithm for Polishing Mixed Integer Programming Solutions.”
Airship Helps DIE ZEIT Turn Silent Advocates into 4.9-Star Rating16.6.2026 15:00:00 CEST | Press release
Leveraging Airship’s Customer Experience Platform, Germany’s leading digital news publisher transforms reader engagement and captures 822 active responses in a single day. Airship, the mobile-first customer experience company, today announced that DIE ZEIT, one of Germany’s largest and most prestigious publishers, has successfully transformed its mobile app presence, lifting the Google Play app store rating from 2.7 stars in early 2026 to a near-perfect 4.9 stars. At a time when many traditional publishers are seeing readership numbers plummet, DIE ZEIT is growing — reaching an all-time high circulation in 2025 and building a digital ecosystem around the brand. The majority of the publication’s readers are now digital, but the publication’s app store rating for DIE ZEIT didn’t match this momentum. DIE ZEIT was up against a universal challenge faced by digital product teams and customer experience executives globally: the "silent advocate" problem. While highly satisfied customers rarel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom